Patent · US Active

Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

US9206402B2 · kind B2 · utility

9Cited by
2References
24Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJun 15, 2012
Grant dateDec 8, 2015
Priority date
Expiry dateNov 26, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Y301/06013
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.